HC Wainwright & Co. Reiterates Buy on Black Diamond Therapeutic, Maintains $11 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Black Diamond Therapeutic (NASDAQ:BDTX) and maintained a price target of $11, as stated by analyst Robert Burns.
September 04, 2024 | 11:28 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Black Diamond Therapeutic and maintained a price target of $11, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a price target by a reputable analyst can positively influence investor sentiment and potentially lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100